학술논문
Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil.
Document Type
Academic Journal
Author
Marra AR; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States.; Miraglia JL; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Malheiro DT; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Guozhang Y; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Teich VD; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Victor EDS; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Pinho JRR; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Cypriano A; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Vieira LW; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Polonio M; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Ornelas RH; Hospital Israelita Albert Einstein, São Paulo, Brazil.; de Oliveira SM; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Borges FA; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Oler SCC; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Ricardo VCV; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Maezato AM; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Callado GY; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Schettino GPP; Hospital Israelita Albert Einstein, São Paulo, Brazil.; de Oliveira KG; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Santana RAF; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Malta FM; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Amgarten D; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Boechat AL; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Kobayashi T; Department of Internal Medicine, University of Iowa, Iowa City, Iowa, United States.; Salinas JL; Stanford University, Stanford, California, United States.; Edmond MB; West Virginia University School of Medicine, Morgantown, West Virginia, United States.; Rizzo LV; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Source
Publisher: Cambridge University Press Country of Publication: England NLM ID: 9918266096106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2732-494X (Electronic) Linking ISSN: 2732494X NLM ISO Abbreviation: Antimicrob Steward Healthc Epidemiol Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
Objective: To compare the long-term vaccine effectiveness between those receiving viral vector [Oxford-AstraZeneca (ChAdOx1)] or inactivated viral (CoronaVac) primary series (2 doses) and those who received an mRNA booster (Pfizer/BioNTech) (the third dose) among healthcare workers (HCWs).
Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) in Brazil from January 2021 to July 2022. To assess the variation in the effectiveness of booster dose over time, we estimated the effectiveness rate by taking the log risk ratio as a function of time.
Results: Of 14,532 HCWs, coronavirus disease 2019 (COVID-19) was confirmed in 56.3% of HCWs receiving 2 doses of CoronaVac vaccine versus 23.2% of HCWs receiving 2 doses of CoronaVac vaccine with mRNA booster ( P < .001), and 37.1% of HCWs receiving 2 doses of ChAdOx1 vaccine versus 22.7% among HCWs receiving 2 doses of ChAdOx1 vaccine with mRNA booster ( P < .001). The highest vaccine effectiveness with mRNA booster was observed 30 days after vaccination: 91% for the CoronaVac vaccine group and 97% for the ChAdOx1 vaccine group. Vacine effectiveness declined to 55% and 67%, respectively, at 180 days. Of 430 samples screened for mutations, 49.5% were SARS-CoV-2 delta variants and 34.2% were SARS-CoV-2 omicron variants.
Conclusions: Heterologous COVID-19 vaccines were effective for up to 180 days in preventing COVID-19 in the SARS-CoV-2 delta and omicron variant eras, which suggests the need for a second booster.
Competing Interests: All authors report no conflict of interest relevant to this article.
(© The Author(s) 2023.)
Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) in Brazil from January 2021 to July 2022. To assess the variation in the effectiveness of booster dose over time, we estimated the effectiveness rate by taking the log risk ratio as a function of time.
Results: Of 14,532 HCWs, coronavirus disease 2019 (COVID-19) was confirmed in 56.3% of HCWs receiving 2 doses of CoronaVac vaccine versus 23.2% of HCWs receiving 2 doses of CoronaVac vaccine with mRNA booster ( P < .001), and 37.1% of HCWs receiving 2 doses of ChAdOx1 vaccine versus 22.7% among HCWs receiving 2 doses of ChAdOx1 vaccine with mRNA booster ( P < .001). The highest vaccine effectiveness with mRNA booster was observed 30 days after vaccination: 91% for the CoronaVac vaccine group and 97% for the ChAdOx1 vaccine group. Vacine effectiveness declined to 55% and 67%, respectively, at 180 days. Of 430 samples screened for mutations, 49.5% were SARS-CoV-2 delta variants and 34.2% were SARS-CoV-2 omicron variants.
Conclusions: Heterologous COVID-19 vaccines were effective for up to 180 days in preventing COVID-19 in the SARS-CoV-2 delta and omicron variant eras, which suggests the need for a second booster.
Competing Interests: All authors report no conflict of interest relevant to this article.
(© The Author(s) 2023.)